2616 fundamentals
An in-depth look to CSTONE PHARMACEUTICALS operating, investing, and financing activities
2616 free cash flow for H2 23 is -320.85 M HKD. For 2023, 2616 free cash flow was -711.43 M HKD and operating cash flow was -639.55 M HKD.
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: HKD
TTM